[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,003,218
  • Shares Outstanding, K 147,754
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 1,815 M
  • EBITDA $ 2,889 M
  • 60-Month Beta 0.17
  • Price/Sales 3.15
  • Price/Cash Flow 9.31
  • Price/Book 1.65

Options Overview Details

View History
  • Implied Volatility 31.92% (+0.31%)
  • Historical Volatility 43.10%
  • IV Percentile 18%
  • IV Rank 18.78%
  • IV High 50.85% on 10/16/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 6) 5.52 (2.63%)
  • Put/Call Vol Ratio 0.60
  • Today's Volume 1,985
  • Volume Avg (30-Day) 1,597
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 46,051
  • Open Int (30-Day) 46,144
  • Expected Range 204.31 to 215.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.87
  • Number of Estimates 16
  • High Estimate $4.28
  • Low Estimate $1.71
  • Prior Year $4.81
  • Growth Rate Est. (year over year) -40.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
186.02 +12.80%
on 07/15/26
218.59 -4.01%
on 07/29/26
+17.88 (+9.31%)
since 07/14/26
3-Month
184.90 +13.48%
on 06/02/26
219.72 -4.50%
on 06/29/26
+18.46 (+9.65%)
since 05/14/26
52-Week
131.52 +59.54%
on 08/29/25
219.72 -4.50%
on 06/29/26
+74.89 (+55.50%)
since 08/14/25

Most Recent Stories

More News
Biogen Completes Acquisition of RayThera Inc.

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on...

BIIB : 209.83 (-0.39%)
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 31.27 (-0.13%)
BIIB : 209.83 (-0.39%)
The 5 Most Interesting Analyst Questions From Biogen’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From Biogen’s Q2 Earnings Call

BIIB : 209.83 (-0.39%)
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027 – – Pre-NDA...

STOK : 31.27 (-0.13%)
BIIB : 209.83 (-0.39%)
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook

BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook

BIIB : 209.83 (-0.39%)
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026

Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026

BIIB : 209.83 (-0.39%)
Can Biogen's Revenue Decline Finally Slow After Two Years of Contraction?

Barchart Research What to Expect from BIIB Earnings BIIB Generated July 28, 2026 Current Price $205.61 EPS Estimate $$1.09 Consensus Rating Moderate Buy Average Move 3.09% Can Biogen's Revenue Decline...

BIIB : 209.83 (-0.39%)
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings

Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings

BIIB : 209.83 (-0.39%)
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 31.27 (-0.13%)
BIIB : 209.83 (-0.39%)
3 Profitable Stocks We Steer Clear Of

3 Profitable Stocks We Steer Clear Of

RVLV : 23.69 (-1.95%)
OCSL : 12.98 (-0.61%)
BIIB : 209.83 (-0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 213.58
2nd Resistance Point 212.18
1st Resistance Point 211.01
Last Price 209.83
1st Support Level 208.44
2nd Support Level 207.04
3rd Support Level 205.87

See More

52-Week High 219.72
Last Price 209.83
Fibonacci 61.8% 186.03
Fibonacci 50% 175.62
Fibonacci 38.2% 165.21
52-Week Low 131.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.